Published in Thromb Res on April 14, 2011
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens (2007) 1.58
Accreditation of medical laboratories in the European Union. Clin Chem Lab Med (2007) 1.55
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost (2011) 1.52
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens (2004) 1.45
Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care (2003) 1.40
Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol (2004) 1.37
In vivo roles of factor XII. Blood (2012) 1.37
Platelet dysfunction in patients with severe traumatic brain injury. J Neurotrauma (2007) 1.15
A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res (2009) 1.14
Concentrations of vitamin C, vitamin B12 and folic acid in patients treated with hemodialysis and on-line hemodiafiltration or hemofiltration. Scand J Urol Nephrol (2008) 1.04
Improved screening for silent atrial fibrillation after ischaemic stroke. Europace (2012) 1.03
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol (2010) 1.03
Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ (2013) 0.96
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens (2002) 0.95
Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers. J Neurotrauma (2007) 0.95
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens (2002) 0.90
Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol (2006) 0.89
Vitamin E isoform-specific inhibition of the exercise-induced heat shock protein 72 expression in humans. J Appl Physiol (1985) (2005) 0.89
Marked increase of fibrin gel permeability with very low dose ASA treatment. Thromb Res (2005) 0.88
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens (2004) 0.88
Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study. J Cardiovasc Pharmacol (2013) 0.87
A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost (2007) 0.84
Changes in von Willebrand factor and ADAMTS13 during IVF. Blood Coagul Fibrinolysis (2011) 0.84
Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations? Clin Chem Lab Med (2008) 0.84
Optimizing centrifugation of coagulation samples in laboratory automation. Clin Chem Lab Med (2014) 0.84
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. Scand J Clin Lab Invest (2013) 0.83
Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res (2007) 0.83
Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost (2012) 0.83
Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion (2003) 0.83
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis (2007) 0.83
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis (2005) 0.82
Hormonal regulation of circulating C-reactive protein in men. Clin Chem (2005) 0.82
In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis (2013) 0.82
The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost (2010) 0.81
Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. Platelets (2013) 0.81
Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis. J Cardiovasc Pharmacol (2009) 0.81
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol (2004) 0.81
Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. BMC Cardiovasc Disord (2003) 0.80
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome. Thromb Res (2007) 0.80
Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost (2012) 0.80
Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res (2011) 0.80
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis (2003) 0.80
On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis (2003) 0.79
Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease. Blood Coagul Fibrinolysis (2016) 0.79
Leukocyte-derived microparticles and scanning electron microscopic structures in two fractions of fresh cerebrospinal fluid in amyotrophic lateral sclerosis: a case report. J Med Case Rep (2012) 0.79
Renal function in community-dwelling frail elderly. Comparison between measured and predicted glomerular filtration rate in the elderly and proposal for a new cystatin C-based prediction equation. Aging Clin Exp Res (2008) 0.79
Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun (2012) 0.79
Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets (2014) 0.78
Clotting onset time may be a predictor of outcome in human brain injury: a pilot study. J Neurosurg Anesthesiol (2003) 0.78
CD40L expression in plasma of volunteers following LPS administration: A comparison between assay of CD40L on platelet microvesicles and soluble CD40L. Platelets (2014) 0.78
Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens (2005) 0.78
Frequency of extreme differences and clinical performance of glucose concentration measurements judged from 21 000 duplicate measurements. Clin Chem (2013) 0.78
Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis (2005) 0.77
Estimated GFR. Comparison of five algorithms:implications for drug dosing. J Clin Pathol (2014) 0.77
Microparticles and microscopic structures in three fractions of fresh cerebrospinal fluid in schizophrenia: case report of twins. Schizophr Res (2012) 0.77
Platelet activation during exercise is not attenuated by inhibition of the renin angiotensin system: the role of physical activity. J Hypertens (2013) 0.76
Are results of fibrinogen measurements transferable? Clin Chem Lab Med (2003) 0.76
Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res (2011) 0.76
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus. Blood Coagul Fibrinolysis (2009) 0.76
Is the combination of trueness and precision in one expression meaningful? On the use of total error and uncertainty in clinical chemistry. Clin Chem Lab Med (2016) 0.76
Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry. Scand J Clin Lab Invest (2011) 0.75
Estimation of uncertainty in measurements in the clinical laboratory. Clin Chem Lab Med (2013) 0.75
Fibrin clot properties and haemostatic function in men and women with type 1 diabetes. Thromb Haemost (2014) 0.75
Exercise-induced platelet activation in essential hypertension: have we solved the puzzle? Reply. J Hypertens (2013) 0.75
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Thromb Res (2002) 0.75
Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system. Thromb Haemost (2016) 0.75
A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor. Br J Haematol (2013) 0.75
Diagnosis of late presenting subarachnoid hemorrhage: comparison of methods for cerebrospinal fluid ferritin. Scand J Clin Lab Invest (2014) 0.75
Can EDTA, EDTA-fluoride, and buffered citrate tubes be used for measurement of HbA1c on the Bio-Rad D10? Clin Chem Lab Med (2015) 0.75
Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger. Thromb Haemost (2014) 0.75
In vitro assessment of platelet concentrates with multiple electrode aggregometry. Platelets (2014) 0.75
Comparison of the 99th percentiles of three troponin I assays in a large reference population. Clin Chem Lab Med (2013) 0.75
Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin. Thromb Res (2003) 0.75
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women. Fertil Steril (2002) 0.75
Extending laboratory automation to the wards: effect of an innovative pneumatic tube system on diagnostic samples and transport time. Clin Chem Lab Med (2016) 0.75
[Chest pain in women with low risk of coronary disease. Think of coronary artery dissection]. Lakartidningen (2010) 0.75
[Myocardial infarction with normal coronary arteries in women. MINCA--a specific type of myocardial infarction]. Lakartidningen (2007) 0.75
Does creatinine analytical performance support robust identification of acute kidney injury within individual laboratories in a region. Clin Chem Lab Med (2015) 0.75